Tendencias de resistencia antimicrobiana en Staphylococcus aureus y Staphylococcus epidermidis resistentes y susceptibles a meticilina aislados, obtenidos en unidades de cuidados intensivos, 2010-2015 by Castro Orozco, Raimundo et al.
409Rev. Fac. Med. 2019 Vol. 67 No. 3: 409-416
Antimicrobial resistance trends in methicillin-resistant and methicillin-
susceptible Staphylococcus aureus and Staphylococcus epidermidis 
isolates obtained from patients admitted to intensive care units. 2010-2015 
Tendencias de resistencia antimicrobiana en Staphylococcus aureus y Staphylococcus 
epidermidis resistentes y susceptibles a meticilina aislados, obtenidos 
en unidades de cuidados intensivos, 2010-2015
Received: 18/06/2017.  Accepted: 28/11/2017.
Raimundo Castro-Orozco1,2 • Claudia Consuegra-Mayor1 • Gloria Mejía-Chávez1 • Jacqueline Hernández-Escolar1 • Nelson 
Alvis-Guzmán2,3 
1 Universidad de San Buenaventura - Cartagena Campus - Faculty of Health Sciences - Cartagena de Indias D.T. - Colombia.
2 Universidad de Cartagena - Faculty of Economics - Cartagena de Indias D.T. - Colombia.
3 Universidad de la Costa (CUC) - Economics Department - Barranquilla - Colombia.
Corresponding author: Raimundo Castro-Orozco. Facultad de Ciencias de la Salud, Sede Cartagena, Universidad de San Buenaventura. 





Introduction: The emergence and spread of antimicrobial-resistant 
strains in hospitals, mainly in intensive care units (ICU), has become 
a serious public health problem.
Objective: To analyze the temporal trends of bacterial resistance 
phenotypes of methicillin-resistant and methicillin-susceptible 
Staphylococcus aureus and Staphylococcus epidermidis isolates obtained 
from ICU patients of a tertiary hospital in Cartagena, Colombia, between 
2010 and 2015.
Methods: A cross-sectional study was carried out between January 
2010 and December 2015. Methicillin-resistant and Methicillin-
susceptible S. aureus and S. epidermidis isolates (MRSA, MSSA, 
MRSE and MSSE) were used. Culture medium microdilution 
technique was used to detect minimal inhibitory concentration (MIC).
Results: 313 Staphylococcus spp. isolates were identified, and most 
of them were methicillin-resistant (63.6%). Methicillin-resistant S. 
aureus (MRSA) and methicillin-resistant S. epidermidis (MRSE) strains 
represented 13.7% and 27.8%, respectively, of the total sample. The 
highest antibiotic resistance values in MRSA and MRSE isolates were 
observed for the following antibiotics: erythromycin (57.6% and 81.2%, 
respectively), clindamycin (54.6% and 71.0%), ciprofloxacin (48.4% 
and 36.4%) and trimethoprim-sulfametoxazole (36.4% and 51.4%). 
Conclusions: The results reported here suggest the need to rethink 
the control strategies designed to minimize antibiotic resistance in 
the hospital in which the study was conducted.
Keywords: Staphylococcus Aureus; Staphylococcus Epidermidis; 
Staphylococcal Infections; Methicillin Resistance; Methicillin-
Resistant Staphylococcus Aureus; Intensive Care Units (MeSH).
| Resumen |
Introducción. La aparición y la diseminación de cepas resistentes en 
hospitales, principalmente en unidades de cuidado intensivo (UCI), 
se han convertido en un serio problema de salud pública.
Objetivo. Analizar la tendencia de los fenotipos de resistencia de 
Staphylococcus aureus y Staphylococcus epidermidis resistentes y 
susceptibles a meticilina aislados en pacientes atendidos en UCI de un 
hospital de alta complejidad de Cartagena, Colombia, del 2010 al 2015.
Materiales y métodos. Estudio analítico transversal realizado entre 
enero de 2010 y diciembre de 2015. Se utilizaron aislamientos de S. 
aureus y S. epidermidis meticilino-susceptibles y meticilino-resistentes 
(SARM, SASR, SERM y SESM). La técnica de susceptibilidad 
empleada fue el método microdilución en caldo para la detección de 
la concentración mínima inhibitoria.
Resultados. Se identificaron 313 aislamientos de Staphylococcus 
spp., la mayoría resistentes a meticilina (63.6%). Las cepas 
SARM y SERM correspondieron al 13.7% y al 27.8% del total de 
aislamientos, respectivamente. Los mayores porcentajes de resistencia 
en SARM y SERM correspondieron a eritromicina (57.6% y 81.2%, 
respectivamente), clindamicina (54.6% y 71.0%), ciprofloxacina 
(48.4% y 36.4%) y trimetoprima-sulfametoxazol (36.4% y 51.4%). 
Conclusión. Los resultados encontrados sugieren el replanteamiento 
de las estrategias de control de la resistencia antimicrobiana en el 
hospital objeto de estudio. 
Palabras clave: Staphylococcus aureus; Staphylococcus epidermidis; 
Infecciones estafilocócicas; Resistencia a la meticilina; Staphylococcus 
aureus resistente a meticilina; Farmacorresistencia microbiana; 
Unidades de cuidados intensivos (DeCS).
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Introducción
The last 20 years have been characterized by the emergence and 
spread of antibiotic-resistant bacteria, which in turn have become a 
determining factor for the failure of antibiotic therapies, mainly in 
patients admitted to intensive care units (ICU). (1,2) This public health 
problem has serious implications on morbidity and mortality rates, and 
on public health systems stability, provided that both direct and indirect 
economic costs increase heavily due long-term hospitalizations and 
greater drug consumption. (3)
To date, different strategies have been developed to minimize the 
impact this public health problem can have on health systems, including 
appropriate antibiotics prescription, cleaning and disinfection programs, 
antimicrobial stewardship programs, and epidemiological surveillance 
of antimicrobial resistance. (2,4)
It has been estimated that in patients admitted to a hospital the risk 
of contracting a nosocomial infection is ~10%. In addition, said risk 
almost quadruples when the individual is admitted to the ICU, since 
antimicrobial therapy is a common practice in ICU patients. (5,6) 
Moreover, multidrug-resistant bacteria infection susceptibility may 
be higher in these critically ill patients (7-9), which limits treatment 
options and makes mandatory to determine antimicrobial resistance 
profiles among clinical isolates retrieved from said patients.
Given how antimicrobial resistance works, any modification to be 
made in antimicrobial management schemes should be based on both 
antimicrobial resistance surveillance data and bacterial etiology. (10)
Changes made to the antimicrobial management schemes are not 
generally applicable to other hospitals, for they are based on the intrinsic 
characteristics of each hospital and depend on several aspects such as 
the type of hospital (facilities), antibiotics availability, and specific 
local data obtained from monitoring antimicrobial resistance. (11)
Staphylococcus spp. are frequently cultured from hospitalized 
patients and are characterized by being resistant to multiple 
antimicrobials. Methicillin-resistant Staphylococcus aureus (MRSA) 
and methicillin-resistant Staphylococcus epidermidis (MRSE) can be 
used as markers to evaluate antimicrobial resistance time trends in 
critically ill patients. (12-19)
Espinosa et al. (20), in a systematic review on antimicrobial 
resistance in gram-positive cocci in Colombian hospitals, reported a 
higher isolation frequency of methicillin-resistant staphylococci 
in ICU isolates in comparison to non-ICU isolates. (20) This finding 
is consistent with those of Villalobos et al. (16) and Villalobos et al. 
(21), who reported MRSA antibiotic resistance phenotypes and profiles 
in tertiary hospitals in Colombia. In this context, the importance of an 
active in vitro antimicrobial resistance surveillance program should 
be noted.
Effective surveillance of antimicrobial resistant organisms allows 
generating reports that provide necessary information for analyzing 
and monitoring resistance patterns; likewise, these surveillance data 
can be used for making decisions regarding the treatment. (22)
The objective of the present study was to evaluate the temporal 
trends of MRSA and MRSE antibiotic resistance phenotypes from 
isolates obtained between 2010 and 2015 from ICU patients in a 
tertiary hospital located in Cartagena, Colombia. 
Materials and methods
Study population
All S. aureus and S. epidermidis isolates were obtained from patients 
admitted between January 2010 and December 2015 to three different 
ICUs (11 adult ICU beds, 11 pediatric ICU beds, and 6 neonatal ICU 
beds) in a tertiary hospital in Cartagena, Colombia. Samples collection 
was performed before chemotherapy was carried out.
Study design
A cross-sectional study was carried out to evaluate antimicrobial 
resistance trends of methicillin-resistant and methicillin-susceptible S. 
aureus (MRSA and MSSA, respectively) and methicillin-resistant and 
methicillin-susceptible S. epidermidis (MRSE and MSSE, respectively) 
by using isolates obtained from ICU patients as resistant markers.
Bacterial identification
A MicroScan® Microbiology System (Siemens Healthcare Diagnostics) 
was used to perform an automated identification process of the 
staphylococcal species. 
Antimicrobial susceptibility tests
A MicroScan® automated system (Dade Behring, Sacramento, USA) 
was used to determine antibiotic resistance/susceptibility by using 
the minimal inhibitory concentration (MIC) technique.
Antibiotics
Antibiotic susceptibility was determined for the following antibiotics: 
clindamycin (CLI, R≥4 µg/mL), ciprofloxacin (CIP, R≥4 µg/mL), 
daptomycin (DAP, S ≤1 µg/mL), erythromycin (ERI, R≥8 µg/mL), 
gentamicin (GEN, R≥16 µg/mL), linezolid (LZD, R≥8 µg/mL), 
moxifloxacin (MXF, R≥4 µg/mL), nitrofurantoin (NIT, R≥128 µg/mL), 
oxacillin (OXA, R≥4 µg/mL for S. aureus, R≥0.5 µg/mL for coagulase-
negative staphylococci), penicillin (PEN, R≥0.25 µg/mL), rifampin (RIF, 
R≥4 µg/mL), trimethoprim-sulfamethoxazole (SXT, R≥ 4/76 µg/mL), 
and vancomycin (VAN, R≥16 µg/mL for S. aureus, R≥32 µg/mL for 
coagulase-negative staphylococci). 
MIC interpretive standards for all antimicrobials tested were 
defined according to the standard breakpoints established by the 
Clinical and Laboratory Standards Institute (CLSI). (23) Isolates 
were classified as sensitive (S) or resistant (R); besides, strains with 
intermediate sensitivity (I) were included in the latter category.
Statistical Analysis
IBM SPSS Statistics for Windows, version 23.0, was used for statistical 
analysis. Annual absolute and relative resistance frequencies were 
analyzed. For dichotomous outcomes effect size in terms of odds 
ratio (24) and associated 95% confidence intervals, 95%CI were 
411Rev. Fac. Med. 2019 Vol. 67 No. 3: 409-16
used. Fisher´s exact test was performed in order to compare antibiotic 
resistance percentages between S. aureus and S. epidermidis isolates, 
and Chi-square test for linear trends was used to analyze the 6-years 
resistance trend. 
All tests of significance were calculated with a two-tailed alpha of 
5%, and multiple antibiotic resistance (MAR) index was determined 
using the procedure described by Krumperman (25). 
Ethical considerations
The study was approved by the Bioethics Committee of Universidad 
de San Buenaventura (Affidavit 005/August-19-2014), which classified 
it as a risk-free research according to the provisions of article 11 of 
Resolution 8430/1993, issued by the Colombian Ministry of Health 
(26), provided that the data used here were obtained from bacterial 
strains collected from patients admitted to ICUs. Likewise, the ethical 
principles for medical research involving human subjects outlined by 
the Declaration of Helsinki were followed. (27)
Results
A total of 313 staphylococcal strains were isolated and identified, of 
which 63.6% (199/313; 95%CI 58.1- 68.7) were methicillin-resistant 
staphylococcal isolates (Table 1: MRSA + MRSE + other MR-CoNS). 
Said isolates were obtained from patients admitted to the adult ICU 
(AICU) (57.1%; 93/163; 95%CI: 49.4- 64.4), the neonatal ICU (NICU) 
(78.8%; 67/85; 95%CI: 69.0-86.2), and the pediatric ICU (PICU) 
(60.0%; 39/65; 95%CI: 47.9-71.0) (Table 1).
Table 1. Distribution of methicillin-resistant and methicillin-susceptible Staphylococcus species isolates according by type of intensive care unit service. 2010-2015.
AICU PICU NICU
n (%) 95%CI n (%) 95%CI n (%) 95%CI
MSSA 34 (20.9) 15.3 to 27.7% 14 (21.5) 13.3 to 33.0% 3 (3.5) 1.2 to 9.9%
MRSA 27 (16.6) 1.6 to 23.0% 11 (16.9) 9.7 to 27.8% 5 (5.9) 2.5 to 13.0%
MSSE 17 (10.4) 6.6 to 16.1% 7 (10.8) 5.3 to 20.6% 5 (5.9) 2.5 to 13.0%
MRSE 28 (17.2) 12.2 to 23.7% 14 (21.5) 13.3 to 33.0% 45 (52.9) 42.4 to 63.2%
Other MS-CoNS 19 (11.6) 7.6 to 17.5% 5 (7.7) 3.3 to 16.8% 10 (11.8) 6.5 to 20.3%
Other MR-CoNS 38 (23.3) 17.5 to 30.4% 14 (21.5) 13.3 to 33.0% 17 (20.0) 12.9 to 29.7%
Total 163 65 85
AICU: adult intensive care unit; PICU: pediatric intensive care unit; NICU: neonatal intensive care unit; MSSA: methicillin-susceptible S. aureus; MRSA: 
methicillin-resistant S. aureus; MSSE: methicillin-susceptible S. epidermidis; MRSE: methicillin-resistant S. epidermidis; MS-CoNS: methicillin-susceptible 
coagulase-negative staphylococci; MR-CoNS: methicillin-resistant coagulase-negative staphylococci. 
Source: Own elaboration.
According to the six years susceptibility test results , methicillin 
resistance rates of S. aureus and S. epidermidis for the whole period 
were 45.7% (43/94; 95%CI: 36.0-55.8) and 75.0% (87/116; 95%CI: 
66.4-82.0), respectively. 
Regarding species identification, by using the automated identification 
system it was found that 53.0% (116/219; 95%CI: 43.4-59.5) of the 
coagulase-negative Staphylococcus (CoNS) that were tested belonged 
to the S. epidermidis species, while 15.5% (34/219; 95%CI: 
11.3-20.9), to S. hominis subsp hominis, and 11.4% (25/219; 
95%CI: 7.9-16.3) to S. haemolyticus. The remaining 20.1% of isolates 
belonged to other coagulase-negative staphylococci (CoNS) species, 
including S. auricularis, S. hominis subsp novobiosepticum, S. warneri, 
S. lugdunensis, S. simulans, S. xylosus, S. intermedius, S. sciuri, S. capitis 
subsp capitis, and S. capitis subsp urealyticus. 
Resistance to methicillin was detected in 71.2% (156/219; 95%CI: 
64.9-76.8) of the CoNS isolates. In addition, 13.7% (43/313; 95%CI: 
10.4-18.0) and 27.8% (87/313; 95%CI: 23.1-33.0) isolates were 
MRSA and MRSE, respectively (Table 1). 
Sample-based MRSA, MSSA, MRSE, and MSSE isolates distribution 
is shown in Table 2. Most of these strains (52.9 to 96.6%) were isolated 
from blood cultures, while the remaining ones were obtained from 
orotracheal and ocular secretions (<30%), and other body fluids (<10%).
Table 2. Distribution of methicillin-resistant and methicillin-susceptible Staphylococcus species isolates based on the sample type they were retrieved from. 2010-2015.
MSSA MRSA MSSE MRSE
n (%) 95%CI n (%) 95%CI n (%) 95%CI n (%) 95%CI
Blood 27 (52.9) 39.5 to 66.0% 24 (55.8) 41.1 to 69.6% 28 (96.6) 82.8 to 99.4% 74 (85.1) 76.1 to 91.1%
Secretions * 15 (29.4) 18.7 to 43.0% 12 (27.9) 16.8 to 42.7% 0 (0) 0.0 to 11.7% 6 (6.9) 3.2 to 14.2%
Fluids † 4 (7.8) 3.1 to 18.5% 4 (9.3) 3.7 to 21.6% 1 (1) 0.6 to 17.2% 1 (1.1) 0.2 to 6.2%
Bronquial 
lavage
3 (5.9) 2.0 to 15.9% 1 (2.3) 0.4 to 12.2% 0 (0) 0.0 to 11.7% 1 (1.1) 0.2 to 6.2%
Urine 2 (3.9) 1.1 to 13.2% 0 (0) 0.0 to 8.2% 0 (0) 0.0 to 11.7% 3 (3.5) 1.2 to 9.7%
Catheter 
tips 
0 (0) 0.0 to 7.0% 2 (4.7) 1.3 to 15.5% 0 (0) 0.0 to 11.7% 2 (2.3) 0.6 to 8.0%
Total 51 43 29 87
MSSA: methicillin-susceptible S. aureus; MRSA: methicillin-resistant S. aureus; MSSE: methicillin-susceptible S. epidermidis; MRSE: methicillin-resistant 
S. epidermidis. 
* Secretions: orotracheal, ocular and other secretions. 
† Fluids: pleural, peritoneal and other fluids.  
Source: Own elaboration.
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Antimicrobial resistance profiles are shown in Table 3. All 
staphylococcal isolates were identified as sensitive to daptomycin 
(DAP). Regarding MRSA and MRSE isolates, the highest 
resistance rates were found for erythromycin (ERI) (57.6% and 
81.2%, respectively), clindamycin (CLI) (54.6% and 71.0%, 
respectively), ciprofloxacin (CIP) (48.4% and 36.4%, respectively) 
and trimethoprim-sulfamethoxazole (SXT) (36.4% and 51.4%, 
respectively).
In addition, resistance percentages to ERI, CLI, gentamicin (GEN), 
CIP, and SXT were far higher in in MRSA than in MSSA isolates. 
A similar behavior was only observed between MRSE and MSSE 
isolates (Table 4).
Table 3. Antimicrobial resistance profiles of the methicillin-resistant and methicillin-susceptible Staphylococcus species isolates. 2010-2015.
MSSA MRSA MSSE MRSE
n (%) 95%CI n (%) 95%CI n (%) 95%CI n (%) 95%CI
CLI 8 (15.7) 8.2 to 28.0% 18 (54.6) 38.9 to 67.5% 3 (14.3) 19.9 to 52.7% 44 (71.0) 51.6 to 71.6%
CIP 1 (3.1) 1.1 to 13.2% 15 (48.4) 26.4 to 54.4% 3 (16.7) 9.9 to 38.4% 20 (36.4) 18.3 to 36.6%
DAP 0 (0) 0.0 to 7.0% 0 (0) 0.0 to 8.2% 0 (0) 0.0 to 11.7% 0 (0) 0.0 to 4.2%
ERI 6 (15.8) 12.5 to 34.6% 19 (57.6) 43.3 to 71.6% 8 (38.1) 31.4 to 65.6% 56 (81.2) 65.9 to 83.6%
GEN 1 (2.5) 0.4 to 10.3% 12 (36.4) 18.6 to 45.1% 4 (19.1) 7.6 to 34.6% 51 (70.8) 58.6 to 77.7%
LZD 0 (0) 0.0 to 7.0% 4 (12.5) 3.7 to 21.6% 0 (0) 0.0 to 11.7% 0 (0) 0.0 to 4.2%
MXF 0 (0) 0.4 to 10.3% 11 (33.3) 14.9 to 40.2% 1 (4.8) 5.5 to 30.6% 7 (11.5) 5.5 to 18.5%
NIT 2 (12.5) 1.1 to 13.2% 3 (23.1) 2.4 to 18.6% 0 (0) 0.0 to 11.7% 0 (0) 0.0 to 4.24%
RIF 1 (2.5) 0.4 to 10.3% 5 (15.2) 5.1 to 24.5% 1 (4.8) 1.9 to 22.0% 22 (30.6) 18.3 to 36.6%
SXT 2 (5) 1.1 to 13.2% 12 (36.4) 16.8 to 42.7% 5 (25) 7.6 to 34.6% 37 (51.4) 32.7 to 53.0%
VAN 0 (0) 0.0 to 7.0% 2 (6.1) 1.3 to 15.5% 1 (4.8) 0.6 to 17.2% 1 (1.4) 0.2 to 6.2%
MSSA: methicillin-susceptible S. aureus; MRSA: methicillin-resistant S. aureus; MSSE: methicillin-susceptible S. epidermidis; MRSE: methicillin-resistant S. 
epidermidis; CLI: clindamycin; CIP: ciprofloxacin; DAP: daptomycin; ERI: erythromycin; GEN: gentamicin; LZD: linezolid; MXF: moxifloxacin; NIT: nitrofurantoin; 
RIF: rifampin; SXT: trimethoprim-sulfamethoxazole; VAN: vancomycin. 
Source: Own elaboration.





p-value* Effect size (OR) 95%CI
CLI-R 0.0001 6.2 2.4 to 15.9
CIP-R ≤0.00001 16.0 3.4 to 74.7
ERI-R 0.0003 5.1 2.1 to 12.3
GEN-R 0.0001 21.7 2.7 to 174.1




p-value* Effect size (OR) 95%CI
CLI-R 0.0097 3.1 1.3 to 7.4
CIP-R 0.536 1.4 0.5 to 3.7
ERI-R 0.0054 3.4 1.4 to 8.0
GEN-R ≤0.00001 10.7 3.8 to 29.9
SXT-R 0.014 3.6 1.3 to 9.8
MSSA: methicillin-susceptible S. aureus; MRSA: methicillin-resistant S. aureus; MSSE: methicillin-susceptible S. epider-
midis; MRSE: methicillin-resistant S. epidermidis; CLI-R: clindamycin-resistant; CIP-R: ciprofloxacin-resistant; ERI-R: 
erythromycin-resistant; GEN-R: gentamicin-resistant; SXT-R: trimethoprim-sulfamethoxazole-resistant.  
* p-values were estimated by means of Fisher’s exact test. 
Source: Own elaboration.
Concerning MSSA strains, all resistance percentage values were 
<20%; on the contrary, resistance percentages to ERI and SXT in 
MSSE isolates were comparable with the high percentage values 
observed in MRSA isolates (p=0.41; X2=0.68 and p=0.296; X2=1.1, 
respectively).
Vancomycin MIC values for 2 MRSA isolates (4.7%; 95%CI: 1.3-
15.5) were 8 µg/mL, vancomycin-intermediate S. aureus (VISA), 
and 16 µg/mL, vancomycin-resistant S. aureus (VRSA), while in 
2 MRSE isolates (2.3%; 95%CI: 0.6-8.0)  vancomycin MIC values 
were ≥16 µg/mL.
Resistance phenotypes trends in MRSA and MRSE isolates were 
higher in the last year of the study (January-December 2015), with the 
exception of resistance to SXT, since SXT-resistant isolates were not 
identified during this period. On the other hand, for the whole six years 
of the study, the lowest resistance percentages in MRSA and MRSE 
isolates were found for SXT (27.9% and 42.5%, respectively) (Table 5).
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Table 5. Trends of antimicrobial resistance phenotypes of methicillin-resistant and methicillin-susceptible Staphylococcus species isolates. 2010-2015.
2010 2011 2012 2013 2014 2015
Resistance 
phenotypes
MRSA MRSE MRSA MRSE MRSA MRSE MRSA MRSE MRSA MRSE MRSA MRSE
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
CLI-R 3 (100) 6 (66.7) 0 (0) 7 (70) 1 (16.7) 7 (63.6) 1 (11.1) 13 (68.4) 12 (92.3) 11 (84.6) 6 (60) 10 (66.7)
ERI-R 3 (100) 16 (100) 0 (0) 8 (80) 3 (50) 8 (72.7) 1 (11.1) 13 (68.4) 12 (92.3) 10 (76.9) 6 (60) 10 (66.7)
CIP-R 1 (100) 6 (66.7) 0 (0) 7 (70) 3 (50) 7 (63.6) 2 (22.2) 13 (68.4) 9 (69.2) 11 (84.6) 2 (20) 3 (20)
GEN-R 3 (100) 11 (68.8) 0 (0) 6 (54.5) 3 (50) 11 (84.6) 0 (0) 13 (68.4) 6 (46.2) 10 (76.9) 1 (10) 9 (60)
SXT-R 2 (66.7) 11 (68.8) 0 (0) 6 (54.5) 5 (83.3) 9 (69.2) 0 (0) 11 (57.9) 5 (38.5) 0 (0) 0 (0) 0 (0)
MSSA: methicillin-susceptible S. aureus; MRSA: methicillin-resistant S. aureus; MSSE: methicillin-susceptible S. epidermidis; MRSE: methicillin-resistant 
S. epidermidis; CLI-R: clindamycin-resistant; CIP-R: ciprofloxacin-resistant; ERI-R: erythromycin-resistant; GEN-R: gentamicin-resistant; SXT-R: trime-
thoprim-sulfamethoxazole-resistant. Note: Multiresistant strains were included individually for each antibiotic evaluated. 
Source: Own elaboration.
Furthermore, in the case of methicillin-resistant isolates, a high 
frequency of multi-drug resistant strains was observed (MRSA: 
26/43; 60.5%; 95%CI: 45.6-73.6; MRSE: 68/87; 78.2%; 95%CI: 
68.4-85.6). In this regard, 28 multiresistant phenotypes (MR-ANT) 
were identified in 26 MRSA (12 MR-ANT) and 68 MRSE (16 MR-
ANT) strains. The MR-Ant frequency order was as follows: CLI-
CIP-ERI-GEN-SXT (MRSA: 19.2%; 5/26; 95%CI: 8.5-37.9; MRSE: 
23.5%; 16/68; 95%CI: 15.0- 34.9), CLI-CIP-ERI (MRSA: 23.1%; 
6/26; 95%CI: 11.0-42.1), CLI-ERI-GEN (MRSE: 14.7%; 10/68; 
95%CI: 8.2-25.0), and CLI-ERI-GEN-SXT (MRSE: 11.8%; 8/68; 
95%CI: 6.1-21.5).
Multiple antibiotic resistances were also observed: 9 isolates 
(MRSA: 2/43; 4.7%; 95%CI: 1.3-15.5; MRSE: 7/87; 8.1%; 95%CI: 
4.0-15.7) were resistant to a combination of seven antibiotics; 22 
(MRSA: 6/43; 14.0%; 95%CI: 6.6-27.3; MRSE: 16/87; 18.4%; 
95%CI: 11.7- 27.8), to a six antibiotics combination, and 13 (MRSA: 
1/43; 2.3%; 95%CI: 0.4-12.1; MRSE: 12/87; 13.8%; 95%CI: 8.1- 
22.6), to a five antibiotics combination.
The highest MAR index values observed in the methicillin-resistant 
Staphylococcus species isolates ranged from 0.8 to 0.9, while in 
methicillin-susceptible strains these ranged from 0.2 and 0.4. In addition, 
in most methicillin-resistant isolates MAR index was higher than 0.2 
(MRSE: 79.3%; 69/87; 95CI 69.7 to 86.5%; MRSA: 60.5%; 26/43; 
95%CI: 45.6-73.6), in contrast with methicillin-susceptible isolates, 
where most of them had a MAR index value lower than 0.2 (MSSE: 
24.1%; 7/29; 95%CI: 12.2-42.1; MSSA: 3.9%; 2/51; 95%CI: 1.1-13.2).
On the other hand, the analysis of the methicillin-resistance trend of 
S. aureus isolates allowed finding a significant increase (p=0.031; X2 
lineal trend=4.673; 1 df; slope=1.72) during the six years study period, 
somehow this epidemiological characteristic was not observed in other 
bacterial strains for the same period (Chi-square for lineal trend, MSSA: 











2010        2011     2012         2013    2014          2015
MSSA  MRSA*   MSSE  MRSE
Figure 1. Frequency of methicillin-resistant and methicillin-susceptible Staphylococcus species isolates. 2010-2015. 
MSSA: methicillin-susceptible S. aureus; MRSA: methicillin-resistant S. aureus; MSSE: methicillin-susceptible S. 
epidermidis; MRSE: methicillin-resistant S. epidermidis. 
* p=0.031; X2 lineal trend=4.673; 1df; m=1.72. 
Source: Own elaboration.
Discussion
Staphylococcus species have emerged as significant pathogens in 
both hospital-acquired and community-onset infections. (28-31) 
Hospital isolates of bacterial strains tend to have higher rates of 
resistance to antimicrobial agents, especially those collected from 
ICU patients. (20)
In this study, a higher frequency of methicillin-resistant staphylococci 
clinical isolates was reported in comparison with methicillin-susceptible 
isolates, which is consistent with the findings of national (16,32-38) and 
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international studies. (12,39-44) In part, this could be explained by the 
relationship between antibiotic selective pressure and the emergence 
of antimicrobial-resistant organisms in hospitals. (45,46)
Most methicillin-resistant strains, mainly MRSE, were isolated 
from patients who were admitted to the NICU. This finding is 
consistent with several works reporting that S. epidermidis is one of the 
most common bacterial pathogens in this population. (32,39,41,43,47-
51) Major risk factors for presenting these staphylococcal infections 
include prematurity, invasive procedures, prolonged hospitalization, 
and immune immaturity. (52,53)
On the other hand, the percentage values of MRSA and MRSE 
strains isolated from blood cultures are similar to those reported by 
Cortes et al. (34) in bacteremic patients admitted to the ICUs of 33 
Colombian hospitals.
All these similarities suggest three possible scenarios at a national 
level: (i) failure of empirical antibacterial therapy (34,54), (ii) 
increased hospital stay lengths for clinically ill patients (55), and 
increased risk of mortality in ICU patients. (34,56)
Also, it was found that MRSE isolates showed a higher resistance 
frequency to antistaphylococcal antibiotics such as ERI, CLI and SXT 
that MRSA strains did. Somehow, in the case of ciprofloxacin, this 
pattern was not observed. Similar results were described by Álvarez 
et al. (57) In an attempt to explain these findings, the authors of the 
present study suggest two key factors: selective pressure caused by 
antibiotic use and cross-transmission of resistant bacteria. 
Significant differences between antimicrobial resistance rates 
of methicillin-resistant and methicillin-susceptible Staphylococcus 
isolates have also been reported by other authors, although they have 
done so when comparing coagulase-negative Staphylococcus strains 
isolated from septicemic patients. (31)
About a third of the methicillin-resistant isolates were also resistant 
to other antibiotics including macrolides, lincosamides, quinolones, 
aminoglycosides, rifamycins, oxazolidinones, nitrofurans and 
antifolates. In addition, if a MAR index value >0.2 can be considered 
a multiple antimicrobial resistance characteristic (58), the presence 
of these multidrug-resistant strains could support the emergence of 
the three hypothetical scenarios described above.
Out of 43 MRSA isolates, 2 vancomycin-intermediate and 
vancomycin-resistant strains were identified in adult bacteremia cases. 
To date, there are no reports of VISA or VRSA isolates in Colombian 
hospitals. (21,33,35-37,49,57) However, one study conducted in 
Caldas, Colombia, in 1996 (38), reported the existence of VRSA 
strains isolated from patients admitted to the ICU, but these isolates 
were identified using the disc diffusion method. Despite the fact 
that VRSA isolates presence has not been confirmed by a reference 
laboratory, this finding could be interpreted as an early warning of 
the occurrence of clinically relevant pathogens for which only limited 
therapeutic options are available. 
A final aspect that should be noted in this context is that in a recent 
study Rossi et al. (59) reported vancomycin resistance transmission 
between MRSA strains isolated from blood cultures.
Conclusion
The most effective antibiotics in MRSA and MRSE isolates were 
daptomycin, linezolid and vancomycin. The significant and rising 
trend in the number of MRSA isolates may be an indication of the need 
to redefine existing strategies to minimize antimicrobial resistance. It 
is necessary to periodically conduct surveillance studies in all hospitals 
in the country to achieve effective control strategies of multi-drug-
resistant infections and to reduce antimicrobial resistance rates. 
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